Aultman Health Foundation

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 2 drugs with upcoming expirations

Activity

Key Events

Mar 23, 2026FDAKetalar — KETALAR

Mar 20, 2026FDAKetalar — KETALAR

Oct 29, 2025FDAKetalar — KETALAR

Nov 22, 2024FDARapiblyk — RAPIBLYK

Jul 11, 2024FDAPitressin — VASOPRESSIN IN SODIUM CHLORIDE 0.9%

Sep 29, 2023FDAPitressin — VASOPRESSIN IN SODIUM CHLORIDE 0.9%

Aug 23, 2022FDAKetalar — KETALAR

Jun 3, 2022FDAKetalar — KETALAR

3 more events

Dec 23, 2019TrialImproving Post-Operative Pain and Recovery in Gynecologic Surgery

Mar 1, 2019TrialStudy of Euthyroid Hypothyroxinemia in Metastatic Breast Carcinoma

Feb 27, 2017TrialVapocoolant Spray Used Prior to Intravenous (IV) Insertions

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

3 patent groups across drugs · Source: FDA Orange Book

DrugExpires

RapiblykApr 25, 2034 Pitressin15 patentsJan 30, 2035 PitressinSep 27, 2044

Regulatory

Regulatory Timeline

20002 events

FDAMar 29

Ketalar — KETALAR

Application NDA016812

FDAMar 14

Ketalar — KETALAR

Application NDA016812

20012 events

FDADec 13

Tigan — TIGAN

Application NDA017531 (NDA)

FDAFeb 14

Ketalar — KETALAR

Application NDA016812

20021 event

FDANov 14

Ketalar — KETALAR

Application NDA016812

20121 event

FDAMar 7

Ketalar — KETALAR

Application NDA016812

20142 events

FDAJul 22

Dantrium — RYANODEX

Application NDA205579 (NDA)

FDAApr 17

Pitressin — VASOSTRICT

Application NDA204485 (NDA)

20171 event

FDAApr 27

Ketalar — KETALAR

Application NDA016812

20181 event

FDAAug 7

Ketalar — KETALAR

Application NDA016812

20202 events

FDAAug 24

Ketalar — KETALAR

Application NDA016812

FDAAug 3

Pitressin — VASOPRESSIN

Application NDA212593 (NDA)

20222 events

FDAAug 23

Ketalar — KETALAR

Application NDA016812

FDAJun 3

Ketalar — KETALAR

Application NDA016812

20231 event

FDASep 29

Pitressin — VASOPRESSIN IN SODIUM CHLORIDE 0.9%

Application NDA217569 (NDA)

20242 events

FDANov 22

Rapiblyk — RAPIBLYK

Application NDA217202 (NDA)

FDAJul 11

Pitressin — VASOPRESSIN IN SODIUM CHLORIDE 0.9%

Application NDA217766 (NDA)

20251 event

FDAOct 29

Ketalar — KETALAR

Application NDA016812

20262 events

FDAMar 23

Ketalar — KETALAR

Application NDA016812

FDAMar 20

Ketalar — KETALAR

Application NDA016812

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)